• Users Online: 866
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 31  |  Issue : 4  |  Page : 163-169

The value of prostate-specific antigen-age volume score in predicting prostate cancer in Taiwan


1 Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
2 Department of Urology, Kaohsiung Medical University Hospital; Department of Urology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan
3 Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung; Department of Urology, Ministry of Health and Welfare Pingtung Hospital, Pingtung; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
4 Department of Urology, Kaohsiung Medical University Hospital; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University; Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
5 Department of Urology, Kaohsiung Medical University Hospital; Department of Urology, Kaohsiung Municipal Siaogang Hospital; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University; Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Correspondence Address:
Jhen-Hao Jhan
Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, No. 100, Shiquan 1st Rd., Sanmin Dist., Kaohsiung City 807
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/UROS.UROS_89_19

Get Permissions

Purpose: Whether the predictive utility of prostate-specific antigen-age volume (PSA-AV) score can surpass serum total PSA, age-adjusted PSA, or PSA density (PSAD) has remained unclear based on previous reports. The aims of this study were to assess the predictive value of PSA-AV score in a Taiwanese population. Materials and Methods: We retrospectively reviewed the medical data of patients who underwent transrectal ultrasound-guided prostate biopsy between 2007 and 2013 at our institution. The ability of serum PSA, age-adjusted PSA, PSAD, and PSA-AV to predict prostate cancer was tested using receiver operating characteristic (ROC) curves. Results: A total of 415 biopsy specimens were included in the study, of which 75 (18.1%) were diagnosed with prostate cancer. The discriminative performance of serum PSA, age-adjusted PSA, PSAD, and PSA-AV for predicting prostate cancer was evaluated in the study cohort. The areas under ROC curve were determined for the four tests as follows: for serum PSA (95% confidence interval [CI]: 0.723–0.852), for age-adjusted PSA (95% CI: 0.719–0.888), for PSAD (95% CI: 0.673–0.877), and for the formula PSA-AV (95% CI: 0.783–0.884), they were 0.787, 0.804, 0.775, and 0.834, respectively. Comparing other tests, the novel formula PSA-AV was significantly better than the other three PSA-derived tests and reached statistical significance (P < 0.05). At this cutoff value (PSA-AV <200), the sensitivity was 74.7% and the specificity was 77.4%. Conclusion: The use of the formula PSA-AV in Taiwan was superior in the prediction of prostate biopsy findings compared to serum PSA, age-adjusted PSA, and PSAD according to our data, particularly in older patients or patients with a larger prostate volume.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed133    
    Printed11    
    Emailed0    
    PDF Downloaded27    
    Comments [Add]    

Recommend this journal